응고 및 지혈 검사 시장 : 제품 유형, 기술, 워크플로우, 검사 유형별, 자동화 레벨, 용도, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The Coagulation & Hemostasis Testing Market is projected to grow by USD 14.17 billion at a CAGR of 11.61% by 2032.

Coagulation and hemostasis testing is a foundational area of clinical diagnostics, supporting the detection, monitoring, and management of bleeding disorders, thrombotic risk, liver disease, sepsis-related coagulopathy, perioperative bleeding, pregnancy complications, and anticoagulant therapy. Core assays such as prothrombin time and international normalized ratio (PT/INR), activated partial thromboplastin time (aPTT), D-dimer, fibrinogen, anti-Xa, platelet function testing, and viscoelastic testing are increasingly embedded across emergency medicine, cardiovascular care, oncology, trauma, intensive care, obstetrics, and surgical pathways.

Demand is supported by measurable public health drivers. The World Health Organization identifies cardiovascular diseases as the leading cause of death globally, accounting for an estimated 17.9 million deaths in 2019. Venous thromboembolism, atrial fibrillation, cancer-associated thrombosis, inherited bleeding disorders, and broader anticoagulant use continue to elevate the importance of accurate, rapid, and standardized hemostasis diagnostics. As health systems prioritize earlier risk stratification, patient blood management, and outcome-based care, coagulation testing is moving from a narrow laboratory function to an essential decision-support capability across the patient journey.

Transformative Shifts in the Testing Landscape

The coagulation and hemostasis testing landscape is being reshaped by the transition from centralized, volume-driven testing toward faster, clinically integrated diagnostics. High-throughput automated analyzers remain critical in hospital and reference laboratories, but point-of-care coagulation testing is gaining traction in operating rooms, emergency departments, anticoagulation clinics, cardiac catheterization laboratories, and critical care units where time-sensitive decisions can affect transfusion use, anticoagulant reversal, thrombosis prevention, and surgical outcomes.

Clinical practice is also shifting as direct oral anticoagulants, anti-Xa monitoring, viscoelastic testing, D-dimer algorithms, and patient-specific bleeding and clotting risk models influence test menus. Laboratories are increasingly expected to deliver not only accurate results but also interpretive value, connectivity with laboratory information systems, quality control traceability, and compliance with evolving accreditation standards. These shifts are creating opportunities for manufacturers and service providers that can combine assay reliability, workflow efficiency, digital integration, and clinician-friendly reporting.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is adding a cumulative layer of value across coagulation and hemostasis testing by improving workflow prediction, quality management, and clinical interpretation. In laboratory operations, AI-enabled analytics can help identify analyzer drift, reagent lot variability, pre-analytical errors, abnormal result patterns, turnaround-time bottlenecks, and reflex testing opportunities. In clinical environments, machine learning models are being studied for venous thromboembolism prediction, bleeding risk stratification, sepsis-associated coagulopathy detection, perioperative risk assessment, and anticoagulation management.

The impact is strongest where AI is implemented as an evidence-based decision-support tool rather than as a replacement for laboratory expertise. U.S. regulatory authorization activity for AI-enabled medical devices has expanded rapidly across healthcare, signaling growing acceptance when performance, validation, bias assessment, and risk controls are demonstrated. For hemostasis testing, the practical advantage lies in combining structured coagulation results with electronic health record data, medication history, comorbidities, imaging, procedure data, and real-time clinical context to support faster, safer, and more consistent decisions.

Key Regional Insights: Asia-Pacific, North America, Europe, Latin America, Middle East & Africa

Asia-Pacific is one of the most dynamic regions for coagulation and hemostasis testing, supported by expanding hospital infrastructure, rising cardiovascular disease burden, larger surgical volumes, and wider adoption of automated diagnostics in China, India, Japan, South Korea, and Australia. Japan and South Korea show strong uptake of advanced laboratory automation and digital hospital workflows, while China and India are expanding access across tertiary hospitals, urban diagnostic networks, and specialty care centers as noncommunicable disease management becomes a higher healthcare priority.

North America remains a high-value regional environment due to advanced hospital laboratories, broad anticoagulation management programs, trauma care networks, and strong adoption of specialty assays and point-of-care coagulation testing. The United States is a leading center for innovation in coagulation analyzers, reagents, informatics, clinical research, and regulatory science, while Canada benefits from organized public healthcare delivery and centralized laboratory systems. Europe benefits from mature laboratory quality systems, national healthcare coverage, and demand for standardized testing across the European Union, the United Kingdom, Germany, France, Italy, and Spain, with the In Vitro Diagnostic Regulation strengthening expectations for clinical evidence, performance evaluation, and post-market surveillance.

Latin America is advancing through private diagnostic networks, cardiovascular care expansion, and hospital modernization in Brazil and Mexico, although access gaps persist across rural and public-sector systems. The Middle East is investing in tertiary care, transplant programs, trauma centers, cardiovascular services, and specialty diagnostics, particularly in GCC countries with high healthcare infrastructure spending. Africa presents long-term potential as laboratory capacity improves, with current demand concentrated in urban hospitals and donor-supported healthcare systems addressing maternal health, surgery, infectious disease, transfusion safety, and emergency care.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7 & NATO

ASEAN markets are gaining momentum as Indonesia, Thailand, Vietnam, Malaysia, the Philippines, and Singapore strengthen hospital laboratory capacity and expand access to chronic disease management. Demand is rising for reliable PT/INR, D-dimer, fibrinogen, and perioperative coagulation testing, with Singapore serving as a regional hub for advanced diagnostics, laboratory accreditation practices, and clinical quality benchmarks.

The GCC is characterized by strong healthcare investment, high hospital spending, and the development of specialized centers for cardiovascular disease, oncology, trauma, transplant medicine, and complex surgery, all of which increase the need for sophisticated hemostasis testing. The European Union continues to emphasize diagnostic standardization, CE-marked technologies under the In Vitro Diagnostic Regulation framework, and cross-border quality expectations that influence procurement, validation, clinical evidence, and post-market performance practices.

BRICS economies represent a major volume environment because they combine large populations, rising noncommunicable disease burdens, expanding tertiary hospitals, and growing diagnostic networks. G7 countries lead in high-value adoption of automation, specialty assays, viscoelastic testing, point-of-care systems, and data-enabled laboratory platforms. NATO countries, with overlapping membership across North America and Europe, sustain demand through advanced emergency medicine, military trauma care, blood management programs, civil preparedness, and resilient healthcare infrastructure planning.

Key Country Insights Across Major Coagulation Testing Markets

The United States leads in clinical adoption, reimbursement maturity, and innovation for coagulation and hemostasis testing, supported by large hospital networks, reference laboratories, anticoagulation services, and FDA-regulated diagnostic pathways. Canada shows steady demand through publicly funded healthcare systems, centralized laboratory models, and quality-focused diagnostic services, while Mexico is advancing through private hospitals, diagnostic chains, and cardiovascular care expansion. Brazil is the largest Latin American opportunity, driven by tertiary hospital investment, public and private diagnostic demand, and increasing focus on cardiovascular and surgical care.

In Europe, the United Kingdom, Germany, France, Italy, and Spain maintain strong demand for routine and specialty hemostasis testing through established hospital laboratories, national healthcare systems, and guideline-driven clinical pathways. Germany is especially influential in laboratory automation, quality-driven procurement, and advanced clinical laboratory infrastructure, while France, Italy, and Spain support demand through cardiovascular, oncology, obstetric, and surgical care. Russia retains substantial testing needs across large hospital systems, although procurement dynamics may be affected by economic conditions, regulatory constraints, and trade limitations.

China and India are major growth engines due to population scale, rising cardiovascular and diabetes burden, hospital expansion, increasing surgical volumes, and broader use of automated analyzers in tertiary and urban diagnostic settings. Japan emphasizes high-quality diagnostics, aging-population care, anticoagulation management, and advanced laboratory systems. Australia has a sophisticated diagnostic environment with strong quality standards and established pathology networks, while South Korea combines advanced hospital infrastructure, digital health readiness, and strong adoption of automated clinical laboratory technologies.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically differentiated testing portfolios that cover routine coagulation, D-dimer, fibrinogen, anti-Xa, specialty factor assays, platelet function, and viscoelastic testing. Competitive advantage will increasingly depend on reagent stability, analyzer uptime, sample throughput, traceable calibration, quality control performance, cybersecurity readiness, and seamless connectivity with laboratory information systems and electronic health records.

Organizations should invest in point-of-care platforms for emergency, perioperative, trauma, obstetric, cardiac, and anticoagulation settings while maintaining strong central laboratory automation. Partnerships with hospitals, reference laboratories, professional societies, and academic centers can support evidence generation, guideline alignment, workflow validation, and real-world clinical adoption. Leaders should also develop AI-enabled analytics under robust governance, with transparent validation, data privacy controls, bias monitoring, cybersecurity safeguards, and clinician-readable outputs that strengthen trust and adoption.

Research Methodology

This executive summary is developed using a structured secondary research approach aligned with market intelligence best practices. The analysis synthesizes publicly available evidence from health agencies, clinical guidelines, regulatory databases, peer-reviewed literature, hospital laboratory standards, accreditation frameworks, and diagnostic industry disclosures. Key reference areas include cardiovascular disease burden, anticoagulation trends, bleeding disorder management, venous thromboembolism risk, laboratory automation, point-of-care testing, in vitro diagnostic regulation, and AI-enabled healthcare technologies.

The methodology emphasizes triangulation across epidemiological indicators, healthcare infrastructure trends, regulatory developments, clinical adoption patterns, reimbursement environments, laboratory workflow requirements, and regional procurement dynamics. No unsupported market size, market share, or growth-rate claims are used. Insights are framed to support executive decision-making across product strategy, geographic prioritization, competitive positioning, quality management, access planning, and innovation strategy in coagulation and hemostasis testing.

Conclusion

Coagulation and hemostasis testing is evolving from a routine diagnostic category into a high-impact clinical decision-support ecosystem. The convergence of chronic disease burden, anticoagulant use, surgical complexity, trauma care, obstetric risk management, sepsis management, transfusion stewardship, and laboratory automation is expanding the role of accurate and timely hemostasis assessment across healthcare systems.

Future leadership will depend on platforms that deliver reliable assays, faster turnaround times, interoperable data, strong quality controls, and evidence-based AI support. Organizations that align innovation with clinical workflow, regulatory expectations, laboratory performance standards, and regional access needs will be best positioned to create long-term value in the global coagulation and hemostasis testing landscape.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Coagulation & Hemostasis Testing Market, by Product Type

• 7.1. Instruments
  • 7.1.1. Coagulation Analyzers
  • 7.1.2. Point-of-Care Coagulometers
• 7.2. Reagents & Consumables
• 7.3. Software & Services
  • 7.3.1. IVD Informatics Solutions
  • 7.3.2. Maintenance & Support

8. Coagulation & Hemostasis Testing Market, by Technology

• 8.1. Electrochemical Detection
• 8.2. Immunoassays
  • 8.2.1. ELISA
  • 8.2.2. Immunoturbidimetric
• 8.3. Microfluidics
• 8.4. Optical Detection

9. Coagulation & Hemostasis Testing Market, by Workflow

• 9.1. Laboratory Based
• 9.2. Point Of Care

10. Coagulation & Hemostasis Testing Market, by Test Type

• 10.1. aPTT Tests
• 10.2. D-Dimer Tests
• 10.3. Fibrinogen Tests
• 10.4. PT/INR Tests

11. Coagulation & Hemostasis Testing Market, by Automation Level

• 11.1. Manual
• 11.2. Semi Automated
• 11.3. Fully Automated

12. Coagulation & Hemostasis Testing Market, by Application

• 12.1. Bleeding Disorder Evaluation
• 12.2. Thrombotic Disorder Evaluation
• 12.3. Anticoagulant Therapy Monitoring
• 12.4. Perioperative Hemostasis Management
• 12.5. Trauma And Massive Transfusion Management
• 12.6. Liver Disease Assessment

13. Coagulation & Hemostasis Testing Market, by End User

• 13.1. Diagnostic Labs
• 13.2. Hospital Labs
• 13.3. Physician Offices
• 13.4. Research Institutes

14. Coagulation & Hemostasis Testing Market, by Region

• 14.1. Asia-Pacific
• 14.2. North America
• 14.3. Latin America
• 14.4. Europe
• 14.5. Middle East
• 14.6. Africa

15. Coagulation & Hemostasis Testing Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. Coagulation & Hemostasis Testing Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. Competitive Landscape

• 17.1. Market Concentration Analysis, 2025
  • 17.1.1. Concentration Ratio (CR)
  • 17.1.2. Herfindahl Hirschman Index (HHI)
• 17.2. Recent Developments & Impact Analysis, 2025
• 17.3. Product Portfolio Analysis, 2025
• 17.4. Benchmarking Analysis, 2025

18. Company Profiles

• 18.1. Abbott Laboratories
• 18.2. AELAB Guangzhou Co., Ltd.
• 18.3. Autobio Diagnostics Co., Ltd.
• 18.4. Beijing Succeeder Technology Inc.
• 18.5. Bio-Rad Laboratories, Inc.
• 18.6. Bio/Data Corporation
• 18.7. Cardinal Health
• 18.8. Danaher Corporation
• 18.9. Diagnostica Stago SAS
• 18.10. F. Hoffmann-La Roche Ltd.
• 18.11. Haemonetics Corporation
• 18.12. Helena Laboratories Corporation
• 18.13. HemoSonics LLC
• 18.14. HORIBA, Ltd.
• 18.15. IDEXX Laboratories, Inc.
• 18.16. Machaon Diagnostics, Inc.
• 18.17. Medsource Ozone Biomedicals Pvt. Ltd.
• 18.18. Mindray Medical International Limited
• 18.19. QuidelOrtho Corporation
• 18.20. Raj Biosis Private Limited
• 18.21. Randox Laboratories Ltd
• 18.22. Sekisui Medical Co., Ltd.
• 18.23. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
• 18.24. Siemens Healthineers AG
• 18.25. Sterile Safequip USA LLC
• 18.26. Sysmex Corporation
• 18.27. Thermo Fisher Scientific Inc.
• 18.28. Universal Biosensors Pty Ltd.
• 18.29. Werfen S.A.